{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:10:48Z","timestamp":1792149048255,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.schres.2011.04.008","type":"journal-article","created":{"date-parts":[[2011,9,2]],"date-time":"2011-09-02T16:31:08Z","timestamp":1314981068000},"page":"101-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder"],"prefix":"10.1016","volume":"132","author":[{"given":"Steven G.","family":"Potkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ogasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Cucchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2011.04.008_bb0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2011.04.008_bb0010","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.04.008_bb0015","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.schres.2011.04.008_bb0020","series-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) Washington","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.schres.2011.04.008_bb0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.04.008_bb0135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(98)00090-6","article-title":"Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial","volume":"20","author":"Daniel","year":"1999","journal-title":"Ziprasidone Study Group. Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2011.04.008_bb0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.04.008_bb0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2007.08.012","article-title":"Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats","volume":"186","author":"Enomoto","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.schres.2011.04.008_bb0040","unstructured":"Geodon, 2008. [prescribing information]. New York, NY: Pfizer Inc."},{"key":"10.1016\/j.schres.2011.04.008_bb0045","series-title":"ECDEU Assessment Manual for Psychopharmacology","first-page":"534","article-title":"Abnormal Involuntary Movement Scale (AIMS)","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2011.04.008_bb0050","series-title":"US Department of Health, Education, and Welfare Pub. No. (ADM) 76\u2013338","first-page":"217","article-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.schres.2011.04.008_bb0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2011.04.008_bb0060","doi-asserted-by":"crossref","unstructured":"Harvey, P.D., Ogasa, M., Cucchiaro, J., Loebel, A., Keefe, R.S.E., 2011. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schiz Res. 127, 188\u2013194.","DOI":"10.1016\/j.schres.2011.01.004"},{"key":"10.1016\/j.schres.2011.04.008_bb0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2011.04.008_bb0070","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.06.058","article-title":"Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test","volume":"572","author":"Ishiyama","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.schres.2011.04.008_bb0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2011.04.008_bb0080","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1176\/appi.ajp.163.3.426","article-title":"The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity","volume":"163","author":"Keefe","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.04.008_bb0085","unstructured":"Latuda [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals, Inc; 2010."},{"key":"10.1016\/j.schres.2011.04.008_bb0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2011.04.008_bb0095","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.04.008_bb0105","series-title":"Poster presentation at the 162nd Annual Meeting of the American Psychiatric Associating","article-title":"Lurasidone is associated with anxiolytic and antidepressant effects in rodent models","author":"Matsumoto","year":"2009"},{"key":"10.1016\/j.schres.2011.04.008_bb0110","doi-asserted-by":"crossref","unstructured":"Meltzer, H.Y., Cucchiaro, J., Silva, R., Ogasa, M., Phillips, D., Xu J., Kalali, A.H., Schweizer, E., Pikalov, A., Loebel, A., 2011. Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo and olanzapine-controlled study. Am. J. Psychiatry June 15 [Epub ahead of print].","DOI":"10.1176\/appi.ajp.2011.10060907"},{"key":"10.1016\/j.schres.2011.04.008_bb0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4088\/JCP.v69n0219","article-title":"Prevalence of baseline serum glucose and lipid testing in users of second generation antipsychotic drugs: a retrospective, population based study of Medicaid claims data","volume":"69","author":"Morrato","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2011.04.008_bb0115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2011.04.008_bb0120","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2011.04.008_bb0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","article-title":"The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity","volume":"165","author":"Nuechterlein","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2011.04.008_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996411002143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996411002143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:23:26Z","timestamp":1760297006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996411002143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":27,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0920996411002143"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2011.04.008","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2011.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}